Sandoz clinical trials

Formerly part of Novartis, Oct 4, 2023 · source ↗

The registry lists 139 studies whose lead sponsor is Sandoz. 0 are recruiting or about to start. Per ClinicalTrials.gov, last updated Jul 7, 2026.

Studies

Recruiting first, then most recently updated. Showing 50 of 139. List all 139 → · All Novartis studies →

• A PK Study to Compare GME751 (Proposed Pembrolizumab Biosimilar) and US-licensed and EU-authorized Keytruda® in Participants With Stage II and III MelanomaCompletedNCT06153238Phase 1

  Sponsor listed in the registry: Sandoz · First submitted after Sandoz left Novartis

• Comparative PK, PD, Efficacy, and Safety Assessment of the Proposed Ocrelizumab Biosimilar CYB704 and Ocrevus in Participants With Relapsing Multiple SclerosisActive, not recruitingNCT06847724Phase 3

  Sponsor listed in the registry: Sandoz · First submitted after Sandoz left Novartis

• Study to Evaluate the Therapeutic Equivalence and Safety of Fluticasone Furoate and Vilanterol Inhalation Powder 100 mcg/25 mcg and BREO ELLIPTA 100 mcg/25 mcg in Participants With AsthmaWithdrawnNCT07223294Phase 3

  Sponsor listed in the registry: Sandoz · First submitted after Sandoz left Novartis

• A Study to Compare Efficacy, Safety, and Immunogenicity of GME751 and EU-authorized Keytruda in Adult Participants With Untreated Metastatic Non-squamous Non-small Cell Lung Cancer (NSCLC)CompletedNCT06159790Phase 3

  Sponsor listed in the registry: Sandoz · First submitted after Sandoz left Novartis

• Integrated Pharmacokinetics (PK)/Efficacy, Safety, and Immunogenicity Study to Demonstrate Similarity of JPB898, a Proposed Biosimilar to Nivolumab, to Opdivo® in Combination With Yervoy®TerminatedNCT06587451Phase 3

  Sponsor listed in the registry: Sandoz · First submitted after Sandoz left Novartis

• Observational Study, to Assess Treatment Retention of an Adalimumab Biosimilar (Hyrimoz®) in IBD Patients in Real Life SettingActive, not recruitingNCT05633771

  Sponsor listed in the registry: Sandoz · First submitted before Sandoz left Novartis

• A Crossover Bioequivalence Study of Olaparib Tablets, 150 mg (Lek Pharmaceuticals d.d.) and Lynparza® (Olaparib) Tablets 150 mg (AstraZeneca Pharmaceuticals LP), in Patients With Breast Cancer Gene (BRCA) Mutated Ovarian Cancer, Recurrent Ovarian Cancer or Metastatic Breast CancerCompletedNCT05258747Phase 1

  Sponsor listed in the registry: Sandoz · First submitted before Sandoz left Novartis

• Efficacy and Safety of the Combination of Acetylcysteine, Paracetamol and Phenylephrine for the Treatment of Common ColdWithdrawnNCT05070650Phase 3

  Sponsor listed in the registry: Sandoz · First submitted before Sandoz left Novartis

• Non-interventional, Long-term Safety Data Collection of Zarzio® / Filgrastim HEXAL® in Stem Cell DonorsCompletedNCT01766934

  Sponsor listed in the registry: Sandoz · First submitted before Sandoz left Novartis

• Phase III Study Assessing the Efficacy, Safety and Immunogenicity of SOK583A1 Versus Eylea® in Patients With Neovascular Age-related Macular DegenerationCompletedNCT04864834Phase 3

  Sponsor listed in the registry: Sandoz · First submitted before Sandoz left Novartis

• Safety and Efficacy of Omnitrope® (rhGH) in Short Children Born Small for Gestational Age (SGA)CompletedNCT00537914Phase 4

  Sponsor listed in the registry: Sandoz · First submitted before Sandoz left Novartis

• Study to Compare the Pharmacokinetics of Fixed-Dose Combination of Mometasone + Azelastine Nasal Spray to Mometasone and Azelastine Nasal Sprays in Adolescents and Young Adults With Seasonal Allergic RhinitisTerminatedNCT05887843Phase 1

  Sponsor listed in the registry: Sandoz · First submitted before Sandoz left Novartis

• Study of the Efficacy and Safety of Broncho-munal®, Capsules, 7 mg for the Treatment of Acute Uncomplicated Respiratory Tract InfectionsCompletedNCT05588804Phase 3

  Sponsor listed in the registry: Sandoz · First submitted before Sandoz left Novartis

• Efficacy and Safety of Azelastine +Mometasone , Nasal Spray, 140 mcg + 50 mcg, (Sandoz d.d., Slovenia) and Momat Rino Advance, Nasal Spray, 140 mcg + 50 mcg, (Glenmark, India) Administered as a Monotherapy to Patients With Seasonal Allergic Rhinitis.CompletedNCT05590598Phase 3

  Sponsor listed in the registry: Sandoz · First submitted before Sandoz left Novartis

• Prospective, Randomized, Multinational, Multicenter, Double-blind, Placebo and Active Controlled Trial in 4 Parallel-groups of Patients Suffering From Seasonal Allergic RhinitisCompletedNCT05311475Phase 3

  Sponsor listed in the registry: Sandoz · First submitted before Sandoz left Novartis

• Study to Evaluate the Efficacy and Safety of HX575 Hexal AG vs ERYPO® for the Treatment of Anemia in Hemodialysis PatientsCompletedNCT00666835Phase 3

  Sponsor listed in the registry: Sandoz · First submitted before Sandoz left Novartis

• Study of the Safety of Use of Intravitreal SOK583A1 Provided in a Vial KitCompletedNCT05282004Phase 3

  Sponsor listed in the registry: Sandoz · First submitted before Sandoz left Novartis

• This Was a Clinical Study Investigating the Moisturization and Desquamation Effect of AmLactin® Rapid Relief Restoring Lotion + Ceramides on Dry Skin in Healthy Female Volunteers. AmLactin® Rapid Relief is an Over-the-counter CosmeticCompletedNCT04085809Not applicable

  Sponsor listed in the registry: Sandoz · First submitted before Sandoz left Novartis

• Study Investigating PK, PD, Efficacy, Safety, and Immunogenicity of Biosimilar Denosumab (GP2411) in Patients With Postmenopausal OsteoporosisCompletedNCT03974100Phase 3

  Sponsor listed in the registry: Sandoz · First submitted before Sandoz left Novartis

• Study of the Safety of Use of Intravitreal SOK583A1 Provided in a Prefilled SyringeCompletedNCT05161806Phase 3

  Sponsor listed in the registry: Sandoz · First submitted before Sandoz left Novartis

• In Vivo Performance of Oral Liquid Formulations of Budesonide in the Fasted State in Healthy SubjectsCompletedNCT05429775Phase 1

  Sponsor listed in the registry: Sandoz · First submitted before Sandoz left Novartis

• Study of LRG-002 Hard Capsules (Lek d.d., Slovenia) Used in the Prophylaxis of Antibiotic-associated Diarrhea in Adults.CompletedNCT04321460Phase 3

  Sponsor listed in the registry: Sandoz · First submitted before Sandoz left Novartis

• Efficacy and Safety of Acetylcysteine for the Treatment of Acute Uncomplicated RhinosinusitisCompletedNCT04123405Phase 3

  Sponsor listed in the registry: Sandoz · First submitted before Sandoz left Novartis

• Study to Test the Hypothesis of Non-inferior Efficacy and Safety of Ferrum Lek® (Iron (III) Hydroxide Polymaltosate), 100 mg Chewable Tablets (Lek d.d., Slovenia), as Compared With MALTOFER® (Vifor S.A., Switzerland), in Subjects With Mild and Moderate Iron Deficiency Anemia.CompletedNCT03993288Phase 3

  Sponsor listed in the registry: Sandoz · First submitted before Sandoz left Novartis

• Real-world Study of Anti-TNFa Treatment Regimes of Hyrimoz or Zessly in Patients With Crohn´s DiseaseCompletedNCT03890445

  Sponsor listed in the registry: Sandoz · First submitted before Sandoz left Novartis

• GP2013 in the Treatment of Patients With Previously Untreated, Advanced Stage Follicular Lymphoma (ASSIST_FL)CompletedNCT01419665Phase 3

  Sponsor listed in the registry: Sandoz · First submitted before Sandoz left Novartis

• Remission of ICD by Switching Dopamine Agonist to Levodopa/CarbidopaCompletedNCT01683253Phase 4

  Sponsor listed in the registry: Sandoz · First submitted before Sandoz left Novartis

• A Study Comparing the Clinical Equivalence of Two Mometasone Nasal Sprays in the Relief of the Signs and Symptoms of Seasonal Allergic RhinitisCompletedNCT01038427Phase 3

  Sponsor listed in the registry: Sandoz · First submitted before Sandoz left Novartis

• A Study Comparing Two Fluticasone Furoate Nasal Sprays in the Relief of the Signs and Symptoms of Seasonal Allergic RhinitisCompletedNCT01279057Phase 3

  Sponsor listed in the registry: Sandoz · First submitted before Sandoz left Novartis

• An Open, Randomised, Single Dose, 2-period, 2-sequence Crossover Adhesion Study of Two Different Transdermal Patches Containing Rotigotine.TerminatedNCT04183634Phase 1

  Sponsor listed in the registry: Sandoz · First submitted before Sandoz left Novartis

• Study of Loteprednol Etabonate in Adults Undergoing Bilateral Cataract SurgeryCompletedNCT03531697Phase 1

  Sponsor listed in the registry: Sandoz · First submitted before Sandoz left Novartis

• Study to Compare Pharmacokinetics of Tacrolimus Prolonged-release (PR) Capsules and Advagraf® PR Capsules in Stable Kidney Transplant Patients.WithdrawnNCT03978494Phase 1

  Sponsor listed in the registry: Sandoz · First submitted before Sandoz left Novartis

• Long-term Safety Follow-up After Growth Hormone Treatment of Short Children Born Small for Gestational AgeTerminatedNCT01491854Not applicable

  Sponsor listed in the registry: Sandoz · First submitted before Sandoz left Novartis

• A Study Comparing Two Ferric Carboxymaltose Formulations in Patients With Iron Deficiency AnemiaCompletedNCT03399084Phase 1

  Sponsor listed in the registry: Sandoz · First submitted before Sandoz left Novartis

• A Study Comparing Two Rifaximin Tablets in Patients With Travelers' Diarrhea.TerminatedNCT02920242Phase 3

  Sponsor listed in the registry: Sandoz · First submitted before Sandoz left Novartis

• A Local Clinical Study for the Comparative Evaluation of Efficacy and Safety of Angal, Lozenges [Menthol] and ANTI-ANGIN® FORMULA, Lozenges, in Treatment of Patients With a Sore ThroatCompletedNCT03095521Phase 3

  Sponsor listed in the registry: Sandoz · First submitted before Sandoz left Novartis

• Clinical Study for Comparative Assessment of Efficacy and Safety of Angal S, Topical Spray and ANTI-ANGIN® FORMULA, Topical Metered Spray in Treatment of Patients With Uncomplicated Acute Infectious and Inflammatory Diseases of the Pharynx, Accompanied by a Sore ThroatCompletedNCT03095508Phase 3

  Sponsor listed in the registry: Sandoz · First submitted before Sandoz left Novartis

• Clinical Trial to Compare Treatment With GP2017 and Humira® in Patients With Rheumatoid ArthritisCompletedNCT02744755Phase 3

  Sponsor listed in the registry: Sandoz · First submitted before Sandoz left Novartis

• Comparative Efficacy and Safety Study of GP2015 and Enbrel® in Patients With Rheumatoid ArthritisCompletedNCT02638259Phase 3

  Sponsor listed in the registry: Sandoz · First submitted before Sandoz left Novartis

• GP2013 in Japanese Patients With CD20 Positive Low Tumor Burden Indolent B-cell Non-Hodgkin's LymphomaCompletedNCT01933516Phase 1

  Sponsor listed in the registry: Sandoz · First submitted before Sandoz left Novartis

• Randomized, Controlled, Double-blind Multicenter Safety Study to Evaluate the Safety and Immunogenicity of Subcutaneous EPO HEXAL vs. ERYPO® in the Treatment of Anemia Associated With Chronic Renal Insufficiency in Predialysis PatientsTerminatedNCT00701714Phase 3

  Sponsor listed in the registry: Sandoz · First submitted before Sandoz left Novartis

• GP2013 in the Treatment of RA Patients Refractory to or Intolerant of Standard TherapyCompletedNCT01274182Phase 1/2

  Sponsor listed in the registry: Sandoz · First submitted before Sandoz left Novartis

• GP2013 Treatment in Patients With Active Rheumatoid Arthritis, Previously Treated With Rituxan® or MabThera®CompletedNCT02514772Phase 3

  Sponsor listed in the registry: Sandoz · First submitted before Sandoz left Novartis

• Pramipexole and Bromocriptine on Nonmotor Symptoms of Early Parkinson's DiseaseCompletedNCT01673724Phase 4

  Sponsor listed in the registry: Sandoz · First submitted before Sandoz left Novartis

• Study to Assess the Efficacy and Safety of HX575 in the Treatment of Chemotherapy Associated Anemia in Cancer PatientsCompletedNCT00711958Phase 3

  Sponsor listed in the registry: Sandoz · First submitted before Sandoz left Novartis

• Phase III Study Comparing the Efficacy and Safety of LA-EP2006 and Peg-FilgrastimCompletedNCT01516736Phase 3

  Sponsor listed in the registry: Sandoz · First submitted before Sandoz left Novartis

• Phase III Study Comparing the Efficacy and Safety of LA-EP2006 and Neulasta®CompletedNCT01735175Phase 3

  Sponsor listed in the registry: Sandoz · First submitted before Sandoz left Novartis

• Post-authorization Safety Study in CKD Subjects Receiving HX575 i.v.CompletedNCT00632125Phase 4

  Sponsor listed in the registry: Sandoz · First submitted before Sandoz left Novartis

• Study to Compare Safety and Efficacy of HX575 Epoetin Alfa and US-licensed Epoetin AlfaCompletedNCT01693029Phase 3

  Sponsor listed in the registry: Sandoz · First submitted before Sandoz left Novartis

• HX575 Epoetin Alfa Subcutaneously (s.c.) in Chronic Kidney Disease (CKD)CompletedNCT01576341Phase 3

  Sponsor listed in the registry: Sandoz · First submitted before Sandoz left Novartis